Marijuana oil may help with acne, eczema, and rosacea

Could CBD be useful in the fight versus resistant bacterial strains? The results from the University of Queensland in Australia recommend that it is possible. But prior to examining the research study in depth, it works to comprehend the evolution of the relationship in between bacteria and prescription antibiotics.

Since the innovative discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have been a vital tool in the fight versus bacteria and infections. And although we still use the very same tested techniques today, bacteria have progressed. When exposed to prescription antibiotics, specific bacteria, fungi and parasites have the ability to adjust and cancel the effectiveness of the drug by establishing resistance.

It’s worth explaining that antimicrobial resistance was likely to happen anyway, as the hereditary code for bacteria modifications over time. Nevertheless, it is believed that the overuse of prescription antibiotics is a crucial factor that accelerates the development of resistant strains.

According to the World Health Organization, antimicrobial resistance “is a significantly major threat to worldwide public health that requires action in all sectors of government and in society.” This has led scientists to think outside package by trying to recognize substances that could be beneficial in the fight versus harmful bacteria. One of these substances is cannabidiol (CBD), a cannabinoid discovered in Cannabis sativa.

Researchers are trying to find new ways to assault infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that new earth CBD works versus Gram-positive bacteria. Strains of Gram-positive bacteria consist of Staphylococcus aureus (typical in skin infections) and Streptococcus pneumoniae (typical in bacterial pneumonia).

Dr. Blaskovich provided his findings at an annual conference of the American Society for Microbiology. In vitro samples of both types of gram-positive bacteria were treated with synthetic CBD. The outcomes led Dr. Blaskovich to the conclusion that CBD operates at levels comparable to those of prescription antibiotics vancomycin and daptomycin. He also found that CBD appeared to work against gram-positive strains of resistant bacteria, which many standard prescription antibiotics are beginning to stop working.

” In particular, the activity was picked versus the resistant strains of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low tendency to cause resistance and was active versus MRSA biofilms. “

The team also performed another research study using topical CBD to deal with a skin infection in mice. Once again, although the outcomes were positive, lakeshore CBD did not appear to get rid of the infection, however just to lower the number of bacterial cells.

Could CBD become an antibiotic?

While it is simple to hail this work as a considerable advancement in the anti-bacterial abilities of CBD, it is too soon to give up on penicillin.

Although it is believed that the effectiveness of CBD might originate from the method it attacks the biofilm surrounding bacterial cells, the authors are still not sure of the system of action of CBD. They also did not hesitate to explain the drawbacks of the research study. Dr. Blaskovich mentioned that because the outcomes are in the preliminary stages, it is far too early for individuals to begin treating their CBD infections themselves.

The research study was also performed in vitro (outside the body), and there is a risk that the outcomes of medical trials will not be the same. A number of substances have shown anti-bacterial effectiveness in petri meals, however then failed at this crucial phase. It should also be discussed that the two studies were carried out in partnership with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical CBD products.

Nevertheless, this research could be a crucial step forward for CBD and the fight versus antimicrobial resistance. CBD continues to have a good safety profile and is not considered toxic even in big quantities. Thankfully, Dr. Blaskovich and his team strategy to continue their research.

Scroll to top